Friday, May 5, 2023

Acelyrin Raising $540M In IPO

Los Angeles-based biopharmaceuticals company ACELYRIN, which is developing immunology drugs, said Thursday that it has upped its IPO pricing, and is now offering up 30,000,000 shares of its common stock at $18.00 per share. The company currently expects to raise $540.0M in the IPO, before expenses. The company starts trading this morning on the Nasdaq Global Select Market as SLRN. The company's offering is being underwritten by Morgan Stanley, Jefferies, TD Cowen and Piper Sandler.